Acurian Saves Over Three Months of Enrollment Time for a Phase IIb Gastroesophageal Reflux Disease (GERD) Study



The sponsor needed data from this study as quickly as possible in order to begin its phase III trial in patients with symptomatic GERD not completely responsive to proton pump inhibitors.

Read More »